NASDAQ:CBPO China Biologic Products (CBPO) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free CBPO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$118.24▼$120.0550-Day Range$117.88▼$119.9952-Week Range$99.74▼$120.05Volume24,016 shsAverage Volume148,695 shsMarket Capitalization$4.72 billionP/E Ratio33.52Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get China Biologic Products alerts: Email Address Ad MarketBeatYour $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionStart Your Risk-Free Trial Here About China Biologic Products Stock (NASDAQ:CBPO)China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.Read More Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. CBPO Stock News HeadlinesDecember 14, 2023 | bbc.comChina hits back at Trump with tariffs on $60bn of US goodsJune 22, 2023 | marketwatch.comBiologic Excipients industry research covers a wide range of industries with predicted CAGR 10% during 2023-2030March 29, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.May 6, 2023 | marketwatch.comNerve Biologic Products Market 2023-2030: Future Hypothesize and ascending UpdatesApril 16, 2023 | marketwatch.comBiologic Excipients Market by 2030: Future Scope and PredictionsApril 14, 2023 | nypost.comWhat is the US’ ‘One China’ policy, and why is it important?April 9, 2023 | marketwatch.comNerve Biologic Products Market in 2023: Insights and Strategies | 2029March 8, 2023 | marketwatch.comBiologic Excipients Market New Innovations and Future Expansion 2023-2028March 29, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionFebruary 19, 2023 | marketwatch.com2023 Nerve Repair and Re-generation Biologic Products Market Future Innovations, Industry Trends and Demand Forecast 2028February 14, 2023 | yahoo.comNeutropenia Biologic Drug Treatment Global Market Report 2023January 30, 2023 | marketwatch.comBiologic Imaging Reagents Market is anticipated to shown growth by 2028 |91 Report PagesJanuary 3, 2023 | yahoo.comBiologic Imaging Reagents Market will reach to USD 6.40 billion by 2030 : GreyViewsDecember 10, 2022 | marketwatch.comBiologic Injectors Market 2022 Latest Research, Top Impacting Factors, Growth Strategies and Forecast to 2028November 24, 2022 | ft.comChina bars celebrities from endorsing products to boost ‘traditional virtues’October 4, 2022 | reuters.comChina sets oil products export quotas at about 15 million tonnesSeptember 6, 2022 | marketwatch.comNerve Biologic Products market is projected to grow with magnificent CAGR| Exclusive Report Spread Across 91 PagesAugust 12, 2022 | thestreet.comBlood Money -- This Plasma Maker Is Set to SoarJuly 11, 2022 | finance.yahoo.comConnect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022June 9, 2022 | finance.yahoo.comBiologic API CDMO Benchmarking Report 2022: Comprehensive Analysis of Current Outsourcing Trends and PracticesNovember 17, 2021 | apnews.comChina Biologic Privatization Transaction Led by Centurium Capital Wins AVCJ “Deal of the Year - Large Cap”July 27, 2021 | finance.yahoo.comWere Hedge Funds Right About Silgan Holdings Inc. (SLGN)?See More Headlines Receive CBPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for China Biologic Products and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2021Today3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CBPO CUSIPN/A CIK1369868 Webwww.chinabiologic.com Phone861065983111FaxN/AEmployees2,269Year Founded1989Profitability EPS (Most Recent Fiscal Year)$4.28 Trailing P/E Ratio33.52 Forward P/E Ratio30.93 P/E GrowthN/ANet Income$138.81 million Net Margins27.43% Pretax MarginN/A Return on Equity8.32% Return on Assets7.64% Debt Debt-to-Equity RatioN/A Current Ratio12.01 Quick Ratio10.13 Sales & Book Value Annual Sales$503.70 million Price / Sales9.38 Cash Flow$5.01 per share Price / Cash Flow23.93 Book Value$45.09 per share Price / Book2.66Miscellaneous Outstanding Shares39,360,000Free FloatN/AMarket Cap$4.72 billion OptionableOptionable Beta0.47 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Joseph Chow (Age 59)Chairman & CEO Mr. Ming Yang (Age 49)Chief Financial Officer Mr. Ming Yin (Age 43)Sr. VP Key CompetitorsImmunovantNASDAQ:IMVTKrystal BiotechNASDAQ:KRYSRevolution MedicinesNASDAQ:RVMDHalozyme TherapeuticsNASDAQ:HALOIovance BiotherapeuticsNASDAQ:IOVAView All Competitors CBPO Stock Analysis - Frequently Asked Questions How were China Biologic Products' earnings last quarter? China Biologic Products Holdings, Inc. (NASDAQ:CBPO) issued its quarterly earnings results on Sunday, March, 28th. The biopharmaceutical company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.22. The biopharmaceutical company earned $112.10 million during the quarter. China Biologic Products had a trailing twelve-month return on equity of 8.32% and a net margin of 27.43%. What other stocks do shareholders of China Biologic Products own? Based on aggregate information from My MarketBeat watchlists, some companies that other China Biologic Products investors own include Lexicon Pharmaceuticals (LXRX), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD) and Amgen (AMGN). This page (NASDAQ:CBPO) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China Biologic Products Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.